Rosuvastatin Tolerance for People with Statin Side Effects
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a low dose of rosuvastatin (a common statin) in people who have had trouble with statins before. The goal is to see if your body can tolerate this specific dose again, which could help lower your cholesterol without the past side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or older.
- You have had side effects from at least 2 different statins and stopped taking them.
- It has been at least 30 days since you last took a statin.
- You are not pregnant, nursing, or planning to become pregnant.
- You have not had a severe reaction to a statin (like muscle breakdown, severe muscle pain, or a bad allergic reaction).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two cholesterol treatment approaches after a heart attack: a lower dose combination versus a higher dose single medicine. It aims to see which option works well and is tolerable for people after a treated heart attack.
This trial studies how short-term statin therapy changes plaque buildup in heart arteries. It uses CT scans to see if statins can make plaques more stable and reduce heart risks.
This trial tests if the cholesterol-lowering drug rosuvastatin affects how your body adapts to running training. You may join if you are a long-distance runner who needs statin therapy and are willing to track your workouts with a sports watch.
This study tests a new drug called RO7795081 to see if it changes how your body handles two common statins (pitavastatin and rosuvastatin). It is for adults who are overweight or obese but otherwise healthy, and aims to check the safety of the new drug.
This early study tests whether “liver fat” changes how a statin (rosuvastatin) works in children and teens. It may help doctors choose safer or more effective dosing in kids based on biology and a specific genetics marker.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
Hear when a new Statin Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.